Replies to post #8214 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Dew, While we are on the subject, based on presumed acceptance of ATRYN by FDA, what kind of timeline for the 2009 IND's would you think? (Assuming we still have operating funds...) Thanks, bp

[ThomasS]

4 IND's: FVIIa, FIX, rhAAT, CD137.
Methinks we should be expecting a partner to formally sign up for CD137 and rhAAT (LFB or not) by YE 2008.

I can't help but believe that there will be other mab's headed GTC's way for production during the course of 2008/09. There is significant lead time involved for development/production in advance of both a) clinical development of new mab's, and b) in advance of existing patent expirations for existing mab's such as is the case for Rituxan/CD20. (What more proof do the detractors need than CD20?)
We accelerate from here, imo. Not necessarily share price, but definetly pace of activity in Massachusetts.